Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Neutral

Noveris Health Sciences Provides Corporate Update

Noveris Health Sciences Re-Engages R&D Partner on Psilocybin Pipeline Amid Stem Cell Pivot and Insider Sell-Off

By The Northwire Desk — AI Analysis Jun 05, 2026 · 16:20 NVRS · 2.86 Noveris Health Sciences Inc.
Executive Summary
  • Noveris Health Sciences re-engaged Applied Pharmaceutical Innovation (API) under a master services agreement effective May 27, 2026.
  • The company will pay a $20,000 retainer and allocate a minimum of $100,000 for R&D consultancy through the end of fiscal 2026, with no minimum or maximum spend requirements.
  • Management is evaluating transaction structures to acquire a 49% equity interest in Ell Stem Cells for $1 million USD, though no definitive agreement has been executed.
  • Immediate corporate priority remains advancing the existing psilocybin IP portfolio and renewed API collaboration over stem cell initiatives.
Material Impact
  • The $120,000 total commitment to API is immaterial relative to the $2.31 million raised in the March 2026 private placement.
  • This announcement is a direct follow-up to the April 20, 2026 clarification that R&D activities were paused due to funding constraints.
  • The market was already aware of the LIFE Offering proceeds and the strategic pivot toward stem cell distribution.
  • The news does not introduce new capital, regulatory milestones, or commercial partnerships. It is an incremental operational update that aligns with previous guidance.
  • Combined with the recent 99% reduction in former CEO Joshua Bartch's stake, the sentiment leans toward capital preservation rather than aggressive growth.
NVRS · Price
Company Overview
  • Noveris Health Sciences is a pre-revenue biotechnology company focused on developing novel psychedelic-inspired compounds for mental health treatment.
  • Flagship Project: A psilocybin-related intellectual property portfolio consisting of 3 issued patents and 13 pending patent applications focused on compounding, synthesizing, and therapeutic uses.
  • Secondary Initiative: Exploring regenerative medicine through a potential stake in ELL Stem Cells, a registered tissue bank and distributor of extracellular matrices and exosomes.
Read the original news release →

More from Noveris Health Sciences Inc.

May 21, 2026 · 14:12

Founder cashes out completely after boardroom shake‑up, casting a dark shadow over the sudden stem‑cell pivot.

Other Apr 29, 2026 · 12:05

Noveris Health Sciences Inc.

M&A / Property Apr 20, 2026 · 17:25

Noveris Health Sciences Inc.

Regulatory Mar 18, 2026 · 20:20

Noveris Announces Closing of Life Offering

Financings Mar 11, 2026 · 22:58

Noveris Announces Life Offering

Financings Mar 10, 2026 · 16:05

Noveris Announces Resignation Of CEO

Management